IMU

IMUGENE FPO [IMU]
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Healthcare · ASX Small Cap
$0.0630 -3.1%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-03-11
Get alerts when IMU triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track IMU — Free

Active Signals

Bullish Signals

  • RSI is looking oversold — historically a spot where stocks tend to bounce
  • MACD momentum is losing steam
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Drifting lower — down 4.5% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.78, underperforming its peers
  • Critical cash runway (0.2 quarters)
  • Revenue in sharp decline (-60%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (0% of range)
  • Small-cap ($20-100M)
  • Capital raise activity (1 events)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 73% over the past year
  • Poor risk-adjusted returns — Sharpe of -1.6 means lots of volatility for not much reward
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.25%/day)
  • Altman Z-Score distress zone (-0.55 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Broke below 20-day support — that's a level the market was defending, and it just gave way
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -60% — the top line is shrinking

Expected next for IMU

2 Nov 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 26 Oct to 9 Nov
The last 4 moved IMU -4.3% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE Application for quotation of securities - IMU
NONE Cleansing Notice
NONE Application for quotation of securities - IMU
Announcement tone +3pts

Recent ASX Announcements

2026-09-08 Application for quotation of securities - IMU
2026-09-01 Cleansing Notice
2026-09-01 Application for quotation of securities - IMU
2026-09-01 Change of Director's Interest Notice x4
2026-08-28 Corporate Governance Statement and Appendix 4G

Key Metrics

$33.1M
Market Cap
1.8M
Avg Volume
1.5x
Vol Ratio
$0.06 — $0.46
52-Week Range
0.3%
Short Interest
N/A
Cash Runway
-314.0%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 83%
LLeader vs LaggardlaggardRS: -20
IInstitutional SponsorshipweakInst: 9%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:IMU vs NUZIMU vs IPDIMU vs HIQ
Share this analysis

Track IMU and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required